Completed preclinical and clinical trials (see below) indicate that this novel agent has attributes that improve on native doxorubicin including reduction of adverse events, improvement in efficacy and the ability to reach the tumor more quickly.
The final stages of preclinical and clinical testing (as described below) demonstrate that this innovative agent boasts advantages over traditional doxorubicin, such as reduced adverse reactions, improved outcomes, and quicker tumor penetration.